Loading company…
Biomedical company developing oncolytic virus cancer vaccines and therapeutics, based in Shenzhen with Canadian headquarters.
Virogin Biotech Ltd. develops anti-cancer oncolytic virus vaccines and oncolytic virus therapeutics. Established in 2015 and based in Shenzhen, China, with headquarters listed in Canada, the company raised USD 60 million in Series C funding in September 2020, co-led by DH Investments and China Merchants Capital. Korea Investment Partners, Fortune United Partners, Linden Asset Group and unspecified investors also participated. Its plans include deepening clinical projects and continuing pre-clinical research.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in